Results 91 to 100 of about 10,751 (182)

Characteristics of pre-existing interstitial lung disease and pneumonitis associated with ramucirumab and paclitaxel combination treatment.

, 2018
Characteristics of pre-existing interstitial lung disease and pneumonitis associated with ramucirumab and paclitaxel combination treatment.
Sou Katayanagi (5349557), Shigeyuki Kawachi (5349554), Nobuyuki Koyama (2733205)   +2 more
core   +1 more source

Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer Supplementary Tables

, 2023
Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer Supplementary Tables 
Zhanglin Lin Cui (7479356), Anindya Chatterjee (189299), Astra M Liepa (15554777), Julie K Beyrer (15554780), Elizabeth L Hadden (15554783)   +4 more
core   +1 more source

Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer

ESMO Gastrointestinal Oncology
Background: The superiority of paclitaxel/ramucirumab over alternative therapeutic regimens in patients with gastric cancer has yet to be defined. Our aim was to evaluate whether second-line treatment with paclitaxel/ramucirumab is superior compared with
E. Fountzilas, J. Souglakos, J. Alafis, K. Dadouli, A. Koumarianou, N. Tsoukalas, A. Nikolaidi, D. Mauri, M. Karagianni, A. Anna, A. Psyrri, G. Rigakos, A. Avgerinos, M. Theochari, D. Pectasides, G. Oikonomopoulos, A. Vagionas, P. Papakostas, A. Christopoulou, G. Fountzilas, Z. Saridaki   +20 more
doaj   +1 more source

Retrospective study of ramucirumab in patients with advanced gastric cancer.

, 2017
199 Background: Ramucirumab is a human, monoclonal antibody that specifically blocks activation of vascular endothelial growth factor (VEGF) Receptor.
Taroh Satoh, Koji Tanaka, Aya Kato, Masaki Mori, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Tomoki Makino, Daisuke Sakai, Yukinori Kurokawa, Shuji Takiguchi, Toshihiro Kudo, Yuichiro Doki, Makoto Yamasaki   +12 more
core   +1 more source

Comment on: Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies [PDF]

, 2015
The Author(s) 2015. This article is published with open access at Springerlink.com A meta-analysis by Wang et al. [1] assessing hypertension risk with ramucirumab use in patients with cancer was recently published in Clinical Drug Investigation.
David Ferry, Andreas Sashegyi, Allen Melemed, Yong Lin   +3 more
core   +1 more source

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients

Thoracic Cancer, 2019
Background It is unclear whether the chemotherapy response improves after exposure to immunotherapy. Antiangiogenic agents have been shown to stimulate the immune system and cause synergistic effects that stimulate tumor shrinkage.
Ayako Shiono, Kyoichi Kaira, Atsuto Mouri, Ou Yamaguchi, Kosuke Hashimoto, Takahiro Uchida, Yu Miura, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu   +10 more
doaj   +1 more source

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab [PDF]

, 2018
We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m2 intravenously (days 1, 8, 15),
Jean Baptiste Bachet, Naima Mahi, Maria Angeles Gil-Delgado, David Khayat, Olivier Lucidarme   +4 more
core   +1 more source

Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung

Kaohsiung Journal of Medical Sciences
Combining epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an anti‐ vascular endothelial growth factor (VEGF) agent, bevacizumab or ramucirumab, is indicated for advanced lung adenocarcinoma harboring EGFR mutation. This study
Chia‐Yu Kuo, Ming‐Ju Tsai, Jen‐Yu Hung, Mei‐Hsuan Lee, Kuan‐Li Wu, Yu‐Chen Tsai, Cheng‐Hao Chuang, Chung‐Wen Huang, Chin‐Ling Chen, Chih‐Jen Yang, Inn‐Wen Chong   +10 more
doaj   +1 more source

Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis

, 2017
Ramucirumab is a monoclonal antibody against Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) approved for the treatment of several solid tumours. As shown in recent trials results, new-onset hypertension is one of the most frequent adverse events
GENERALI, DANIELE, Daniele Generali, Chiara Pacifico, Giandomenico Roviello, ROVIELLO, GIANDOMENICO, Pacifico, Chiara, Paola Corona, Corona, Paola   +7 more
core   +1 more source

Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: Subgroup analysis from RAINBOW study

, 2019
Aim: This subgroup analysis of the RAINBOW study evaluated the efficacy and safety of ramucirumab in patients with gastric cancer/gastroesophageal junction adenocarcinoma who received prior trastuzumab therapy.
De Vita F., Borg C., Farina G., Carton I., Wei R., Cuku H., Geva R., Muro K.   +7 more
core   +1 more source